Poland· PL-100281177
Cyrdanax
A dexrazoxane product containing dexrazoxanum, registered in Poland by Pharmaselect International Beteiligungs GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Dexrazoxane is registered in 15 of 19 countries.
Countries holding a registration under ATC V03AF02 (dexrazoxane), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Dexrazoxane · ATC V03AF02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dexrazoxane costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dexrazoxane · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- FI Finland$8.88
The record
At a glance
URPL (Poland)- Active substance
- Dexrazoxanum
- Manufacturer
- Pharmaselect International Beteiligungs GmbH
- Country
- Poland (PL)
- ATC code
- V03AF02
- ATC class
- Dexrazoxane
- Defined daily dose
- 1.5 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990984732
- gtin05909990984749
- gtin05909991187859
- gtin05909991187866
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for dexrazoxane.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dexrazoxane · interactions on record
8 records
- 2 severe
- 6 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- Lactobacillus acidophilusJ07AX04moderate
- DoxorubicinL01DB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dexrazoxane in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSaveneOrifarm Oy
- SpainSAVENE 20 mg/ml POLVO PARA CONCENTRADO Y DISOLVENTE PARA SOLUCION PARA PERFUSIONCnx Therapeutics Ireland Limited
- IrelandSavene 20 mg/ml powder and solvent for concentrate for solution for infusionCNX Therapeutics Ireland Limited
- IcelandSaveneCNX Therapeutics Ireland Limited
- NorwaySaveneCNX Therapeutics Ireland Ltd.
- BelgiumSavene 20 mg/mlCnx Therapeutics Ireland
- SwedenSavene 20 mg/ml Pulver till koncentrat och vätska till infusionsvätska, lösningCNX Therapeutics Ireland Ltd
- United StatesDexrazoxaneFosun Pharma USA Inc.
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Cyrdanax
- Czechia · Cyrdanax
- Germany · Cardioxane, Cyrdanax
- Spain · Cardioxane
- France · Cardioxane, Cyrdanax
- United Kingdom (Northern Ireland) · Cardioxane
- Hungary · Cyrdanax
- Iceland · Savene
- Italy · Cardioxane
- Liechtenstein · Savene
- Netherlands · Cardioxane
- Norway · Savene
- Romania · Cyrdanax
- Slovakia · Cyrdanax
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/622c92ff-b40f-4fe3-9011-64484bb04974 GET /v1/drugs/622c92ff-b40f-4fe3-9011-64484bb04974?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "20 mg/ml",
"packaging": "05909990984732 ¦ Rp ¦ 77278\n1 fiol. 250 mg\n05909990984749 ¦ Rp ¦ 77279\n1 fiol. 500 mg\n05909991187859 ¦ Rp ¦ 103677\n4 fiol. 250 mg\n05909991187866 ¦ Rp ¦ 103678\n4 fiol. 500 mg",
"substance": "Dexrazoxanum w zależności od wielkości opakowania: 250 mg lub 500 mg",
"common_name": "Dexrazoxanum",
"pl_product_id": "100281177",
"pozwolenie_nr": "20248",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about dexrazoxane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.